Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51


Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study.

Elmore JG, Tosteson AN, Pepe MS, Longton GM, Nelson HD, Geller B, Carney PA, Onega T, Allison KH, Jackson SL, Weaver DL.

BMJ. 2016 Jun 22;353:i3069. doi: 10.1136/bmj.i3069.


Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.

Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Matsuoka J, Doihara H, Kinoshita T, Nakamura S, Tokuda Y.

Breast Cancer Res Treat. 2016 Apr;156(3):485-94. doi: 10.1007/s10549-016-3770-7. Epub 2016 Apr 5.


Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Hassett MJ, Jiang W, Habel LA, Nekhlyudov L, Achacoso N, Acton L, Schnitt SJ, Schrag D, Punglia RS.

Breast Cancer Res Treat. 2016 Feb;155(3):541-9. doi: 10.1007/s10549-016-3692-4. Epub 2016 Feb 3.


Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.

Kinoshita T, Fukui N, Anan K, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):39-49. doi: 10.1007/s12282-015-0644-5. Epub 2015 Oct 7. No abstract available.


Cancer statistics: Breast cancer in situ.

Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, Brawley OW, Gansler T.

CA Cancer J Clin. 2015 Nov-Dec;65(6):481-95. doi: 10.3322/caac.21321. Epub 2015 Oct 2.


Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.

Mukai H, Arihiro K, Shimizu C, Masuda N, Miyagi Y, Yamaguchi T, Yoshida T.

Breast Cancer. 2016 Jan;23(1):73-7. doi: 10.1007/s12282-015-0640-9. Epub 2015 Sep 30.


Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2015 Nov 20;33(33):3938-44. doi: 10.1200/JCO.2015.60.8588. Epub 2015 Sep 14.


Estimation of the optimal number of radiotherapy fractions for breast cancer: A review of the evidence.

Wong K, Delaney GP, Barton MB.

Radiother Oncol. 2015 Aug;116(2):174-8. doi: 10.1016/j.radonc.2015.07.015. Epub 2015 Aug 10. Review.


The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.

Coromilas EJ, Wright JD, Huang Y, Feldman S, Neugut AI, Chen L, Hershman DL.

JAMA Oncol. 2015 Jun;1(3):323-32. doi: 10.1001/jamaoncol.2015.0389.


The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS scoreā„¢ result.

Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ.

J Surg Oncol. 2015 Jun;111(8):935-40. doi: 10.1002/jso.23933. Epub 2015 May 28.


The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study.

Li Y, Zhang S, Wei X, Zhang J.

Int J Surg. 2015 Jul;19:91-4. doi: 10.1016/j.ijsu.2015.05.013. Epub 2015 May 23.


Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ.

Fancellu A, Turner RM, Dixon JM, Pinna A, Cottu P, Houssami N.

Br J Surg. 2015 Jul;102(8):883-93. doi: 10.1002/bjs.9797. Epub 2015 Apr 28. Review.


Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.

Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH.

Ann Surg Oncol. 2015 Dec;22(13):4263-9. doi: 10.1245/s10434-015-4552-x. Epub 2015 Apr 17.


Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL.

JAMA. 2015 Mar 17;313(11):1122-32. doi: 10.1001/jama.2015.1405.


RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J.

J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20. Erratum in: J Clin Oncol. 2015 Sep 10;33(26):2934.


Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators..

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.


Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Roetzheim RG, Lee JH, Fulp W, Matos Gomez E, Clayton E, Tollin S, Khakpour N, Laronga C, Lee MC, Kiluk JV.

Breast. 2015 Feb;24(1):51-6. doi: 10.1016/j.breast.2014.11.006. Epub 2014 Dec 6.


Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society.

Vatovec C, Erten MZ, Kolodinsky J, Brown P, Wood M, James T, Sprague BL.

Crit Rev Eukaryot Gene Expr. 2014;24(4):281-6. Review.


Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program.

McCarthy AM, Kontos D, Synnestvedt M, Tan KS, Heitjan DF, Schnall M, Conant EF.

J Natl Cancer Inst. 2014 Oct 13;106(11). pii: dju316. doi: 10.1093/jnci/dju316. Print 2014 Nov.

Supplemental Content

Loading ...
Support Center